Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 6/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 2/20 | 0.43 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14672574 | 1.00 | ANO1 (0.47) | ANO1USP30HDAC4HDAC6DDB1 | |
| SCHEMBL2331813 | 0.94 | USP30 (0.50) | USP30HDAC4HDAC6DDB1CRBN | |
| SCHEMBL2331810 | 0.94 | USP30 (0.50) | USP30HDAC4HDAC6DDB1CRBN | |
| SCHEMBL30000193 | 0.87 | ALDH1A1 (0.56) | DDB1CRBNCNR1CNR2ACHE | |
| SCHEMBL1748523 | 0.87 | ALDH1A1 (0.56) | DDB1CRBNCNR1CNR2ACHE | |
| SCHEMBL14675522 | 0.83 | GFER (0.45) | BTKGFER | |
| SCHEMBL21598943 | 0.83 | USP30 (0.55) | USP30HDAC4HDAC6PARP1BTK | |
| SCHEMBL30874489 | 0.82 | BTK (0.48) | ANO1USP30HDAC4HDAC6PARP1 | |
| SCHEMBL21777561 | 0.82 | USP30 (0.48) | ANO1USP30HDAC4HDAC6PARP1 | |
| SCHEMBL21777558 | 0.82 | USP30 (0.48) | ANO1USP30HDAC4HDAC6PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9034311-B2 | Pyridin-2(1 H)-one derivatives as JAK inhibitors | ALMIRALL, S.A. (ES) | 2015-05-19 | — | — | US | disclosed |
| US-20140271543-A1 | PYRIDIN-2(1H)-ONE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2014-09-18 | — | — | US | disclosed |
| EP-2554544-A1 | Pyridin-2(1h)-one derivatives as jak inhibitors | Almirall, S.A. (ES) | 2013-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140271543-A1 | PYRIDIN-2(1H)-ONE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | ANO1 4139/4885USP30 2649/4885HDAC4 3681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.